Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment 2018
In-Person Event
Sep 04 - 06, 2018
Rockville, Maryland, USAOVERVIEW
Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment is organized by National Institute of Allergy and Infectious Diseases (NIAID) and will be held from Sep 04 - 06, 2018 at NIH/NIAID, Rockville, Maryland, United States of America.
Conference Description:
Cytomegalovirus infection causes significant morbidity and mortality in congenitally-infected infants and transplant recipients. There is no licensed vaccine for CMV, and antiviral treatment of CMV infection is challenged by drug toxicities and the emergence of resistant CMV isolates in treated patients. New approaches for both prevention and treatment would have a substantial public health impact in both populations, but numerous challenges have hampered progress in these areas.
Congenital CMV infection is the most common infectious cause of disability in newborn infants. It results in brain damage/developmental delays, and sensorineural hearing loss, and is an occasional cause of mortality. Approximately 13.5% of congenitally-infected newborns are symptomatic. Nearly 50% of symptomatic and 10% of asymptomatic infants develop some degree of hearing loss, and a large proportion of symptomatic infants suffer from some degree of psychomotor and cognitive disabilities, with visual impairment in up to half of the symptomatic infants. Congenital CMV infection occurs in between 0.2% and 0.7% of newborns in the United States and other developed nations, with even higher prevalence in the developing world. Infants carried by seronegative pregnant women acutely infected in pregnancy are at particularly high risk, with up to 32% of primary maternal infections leading to congenital CMV transmission.
This meeting will review the current state of knowledge of CMV disease, including which populations may be most affected, and challenges associated with current diagnostic platforms. The meeting will also facilitate the discovery and development of vaccines and therapeutics for serious CMV infections and/or disease by assessing the state of the art and identifying knowledge gaps and other barriers to the advancement of products.
Additional details will be posted as soon as they are available.
Conference Description:
Cytomegalovirus infection causes significant morbidity and mortality in congenitally-infected infants and transplant recipients. There is no licensed vaccine for CMV, and antiviral treatment of CMV infection is challenged by drug toxicities and the emergence of resistant CMV isolates in treated patients. New approaches for both prevention and treatment would have a substantial public health impact in both populations, but numerous challenges have hampered progress in these areas.
Congenital CMV infection is the most common infectious cause of disability in newborn infants. It results in brain damage/developmental delays, and sensorineural hearing loss, and is an occasional cause of mortality. Approximately 13.5% of congenitally-infected newborns are symptomatic. Nearly 50% of symptomatic and 10% of asymptomatic infants develop some degree of hearing loss, and a large proportion of symptomatic infants suffer from some degree of psychomotor and cognitive disabilities, with visual impairment in up to half of the symptomatic infants. Congenital CMV infection occurs in between 0.2% and 0.7% of newborns in the United States and other developed nations, with even higher prevalence in the developing world. Infants carried by seronegative pregnant women acutely infected in pregnancy are at particularly high risk, with up to 32% of primary maternal infections leading to congenital CMV transmission.
This meeting will review the current state of knowledge of CMV disease, including which populations may be most affected, and challenges associated with current diagnostic platforms. The meeting will also facilitate the discovery and development of vaccines and therapeutics for serious CMV infections and/or disease by assessing the state of the art and identifying knowledge gaps and other barriers to the advancement of products.
Additional details will be posted as soon as they are available.
KEY DATES
04 Sep, 2018
Event Start Date
06 Sep, 2018
Event End Date
SPECIALITIES
Infectious DiseaseSUGGESTED HOTELS
CONFERENCE VENUE
NIH/NIAIDRELATED CONFERENCES & LIVE WEBINARS
Quick Links